Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition ...

The collaboration with Oxford BioTherapeutics complements Boehringer Ingelheim’s development of next-generation life-changing cancer immunotherapies with the identification of unique and ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

G2G Bio partners with Boehringer Ingelheim to develop long-lasting injectable drug G2G Bio collaborates with Boehringer Ingelheim to innovate in injectable drug development ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

Boehringer Ingelheim India and EMRI Green Health Services partner to improve stroke care through specialized training and ...

The Campaign will Donate Millions of Meals and Thousands of Doses of NexGard® PLUS (afoxolaner, moxidectin, and pyrantel ...